mySugr GmbH

FDA product reviews were the lead story for the year, as Class II device designations emerged for large-panel tumor-profiling assays and direct-to-consumer (DTC) genetic health risk assessment (GHRA)

What changes should medtech companies, including those with IT applications, expect from 2018, or, put another way, how should they prepare to serve a global health care sector that is expecting "more

Industry observers had long been waiting for Gilead Sciences Inc. to make a major acquisition, and its $11.9bn purchase of Kite Pharma Inc. fit that bill and helps super-charge its cancer pipe

While technology companies have long tapped into the potential of machine-learning and artificial intelligence to develop smarter, better and cheaper gadgets, a growing wave of health care companies a